Trial
NCT04804033
A Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Pfizer
Collaborators
—
Condition
Migraine
Intervention
BHV-3500 (zavegepant)
Why stopped
Strategic decision to discontinue the study based on adjusted clinical development plan. This decision is not based on any safety concerns.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-03-27